PTC shares soar on EU backing for muscular dystrophy drug

Shares in U.S. biotech company PTC Therapeutics more than doubled in premarket dealings on Friday after European regulators recommended a conditional class="mandelbrot_refrag">marketing authorization for Translarna, its drug for Duchenne muscular dystrophy.

_0">

European Medicines Agency experts had adopted a negative opinion on the drug in January.

Conditional class="mandelbrot_refrag">marketing authorization is an early access mechanism for medicines that address an unmet medical need for patients suffering from life-threatening diseases, even if comprehensive clinical data are not yet available.

(Reporting by Ben Hirschler, Editing by Paul Sandle)

Popular posts from this blog

Study Abroad USA, College of Charleston, Popular Courses, Alumni

Edinburgh Napier University Admission Process

It's 'baa'... not 'bark'! Lamo the sheep is so convinced he's a dog